// App-Quantinova.ai

BSH2020‐PO‐112 : VIM: the results of a phase 1/2 trial of bortezomib, idarubicin and melphalan in relapsed or refractory multiple myeloma

Researchers

Presenter

  • K. Boyd

Principal Investigators

  • F. Davies

  • G. Morgan

  • A. Bonner

  • L. Conneely

  • M. Kabir

  • G. Machell

  • C. Pawlyn

  • R. Saso

  • L. Smith

  • E. Strong

  • M. Kaiser

Medical Centers

  • Department of Haemato‐oncology, Royal Marsden Hospital

  • The Institute of Cancer Research, London, UK

  • Perlmutter Cancer Center NYU Langone, New York, NY

  • Statistics Department, Royal Marsden Hospital, London, UK

Locations

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

  • Oncology (ONC)

Disease

  • Multiple Myeloma

  • Thrombocytopenia

  • Neutropenia

Biomarkers

  • Creatinine

  • Vimentin

Drug/Treatment

  • Bortezomib

  • Idarubicin Hydrochloride

  • Melphalan

Outcome

  • N/A

Study Design

  • Dose Escalation

  • Cohort

  • Single Center

Phase

  • I/II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved